# Boxer Capital

> Boxer Capital is a VC fund backing Biotechnology and Health Care. See 120 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Windermere, United States
- Total investments: 120
- Last investment: Jun 2026
- Lead investor: 15%
- Last updated: Aug 2026
- Website: http://www.tavistock.com/portfolio/tavistock-life-sciences/boxer-capital/

Boxer Capital is a VC fund in Windermere focused on Biotechnology and Health Care. Boxer Capital caters to public companies based in the biotechnology industry.

## Contacts

5 contacts available for Boxer Capital. Shizune tracks 2 team members at Boxer Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/boxer-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 91 | 76% |
| Health Care | 59 | 49% |
| Therapeutics | 48 | 40% |
| Medical | 25 | 21% |
| Pharmaceutical | 22 | 18% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 37 | 31% |
| Series B | 32 | 27% |
| Series C | 18 | 15% |
| Series A | 15 | 13% |
| Series D | 5 | 4% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 79 | 66% |
| Canada | 5 | 4% |
| United Kingdom | 2 | 2% |
| China | 1 | 1% |
| Japan | 1 | 1% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Aaron Davis | Co-Founder and CEO | 0 | https://shizune.co/investors/profile/aaron-davis-6ff2 |
| Dominik Naczynski | Senior Vice President | 1 | https://shizune.co/investors/profile/dominik-naczynski |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M | Series C | Jun 30, 2026 |  |
| Adial Pharmaceuticals | Adial Pharmaceuticals, LLC engages in the development of prescription medications for addiction and related disorders in the United States. The company's research pipeline includes AD04, a compound that completed Phase IIb study for the treatment of alcohol use disorders; and AD01, which completed Phase I clinical-stage for treating addictivebehaviors. | $32M | Post-IPO Equity | Jun 11, 2026 |  |
| Clene Nanomedicine | Clene Nanomedicine is a clinical-stage biopharmaceutical company that focuses on the development of unique therapeutics for neurodegenerative diseases. The company innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs. | $28M | Post-IPO Equity | Jan 09, 2026 |  |
| SeraGene Therapeutics | SeraGene Therapeutics is a biotechnology company that offers treatment for coagulation disorders through nanomedicine technologies and RNA. |  | Seed | Nov 19, 2025 |  |
| Zag Bio | Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M | Series A | Oct 28, 2025 |  |
| Cybin | Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $175M | Post-IPO Equity | Oct 28, 2025 |  |
| Tango Therapeutics | Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused onthree core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy. | $197M | Post-IPO Equity | Oct 23, 2025 |  |
| Palisade Bio | Palisade Bio is a clinical-stage biopharmaceutical company developing treatments for diseases of unmet medical need. They base these treatments on sound science and therapies with a decades-long history of safe and effective usage. The company's mission is to develop and commercialize novel therapeutics that target diseases resulting from aloss of gastrointestinal barrier integrity. The company was founded in 2011 and is headquartered in Carlsbad, California. | $138M | Post-IPO Equity | Oct 01, 2025 |  |
| Crescent Biopharma | Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors. | $200M | Post-IPO Equity | Jun 16, 2025 |  |
| Crescent Biopharma | Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors. | $200M |  | Oct 29, 2024 |  |

10 of 120 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 43 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 30 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 27 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 26 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 25 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 25 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)

## FAQ

### What does Boxer Capital invest in?

Boxer Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 120 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Boxer Capital?

Public channels for Boxer Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Boxer Capital?

The team at Boxer Capital includes Aaron Davis (Co-Founder and CEO) and Dominik Naczynski (Senior Vice President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co